GWM
IMCR icon

Geneos Wealth Management’s Immunocore IMCR Stock Holding History

Geneos Wealth Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$715 – 2123
2024
Q1 		$715 Buy
+11
New +$755 ﹤0.01% 2082
2021
Q4 		– Sell
-4,250
Closed -$163K – 2819
2021
Q3 		$163K Buy
+4,250
New +$143K 0.01% 946

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geneos Wealth Management's IMCR Position: Q2 2024 in Review

Geneos Wealth Management sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 11 shares — an estimated $715 sold.

Geneos Wealth Management first reported a position in IMCR in Q3 2021 and held it in 2 quarters. The position peaked at $163K in Q3 2021. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

  • Geneos Wealth Management reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
  • Geneos Wealth Management sold 11 Immunocore shares in Q2 2024, an estimated $715.
  • Geneos Wealth Management first reported a position in Immunocore in Q3 2021 and held it in 2 quarters.
  • Geneos Wealth Management's Immunocore position peaked at $163K in Q3 2021.
  • 138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on Geneos Wealth Management's 13F filing for Q2 2024, filed 23 Jul 2024.